Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRQR Stock 12 Month Forecast
Average Price Target
$7.25
▲(207.20% Upside)
| Highest Price Target$12.00 | Average Price Target$7.25 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$12
Buy
408.47%
Upside
Reiterated
12/10/25
Positive Outlook for ProQR's AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy RecommendationValuation and Risks. Our price target of $12 is based on a DCF analysis from 2025-2032, with NPV of $12 per share (discounted cash flow analysis using a 20% discount rate and 1% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to our investment thesis and target price include: (1) failure of clinical studies or partnership opportunities; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.
Chardan Capital
$4
Buy
69.49%
Upside
Reiterated
11/06/25
Evercore ISI
$5
Buy
111.86%
Upside
Reiterated
11/04/25
ProQR (PRQR) Receives a Buy from Evercore ISIWe model PSC as a $2B oppty for PRQR (we don’t model BA for now). Candidly, if PRQR has the first truly disease-modifying therapy in PSC, this # should be conservative. But let’s go with it. To reach the current trading price, we find a market-implied 12.5% PoS. After PRQR has their full P1 NTCP HV data in 1H26, we think it’s very reasonable to model a 20% PoS. This would correspond to a $5/sh price – implying 100% upside from now until this PoC data. (25% PoS is also quite defendable, which would correspond to $7/sh) Why not a higher PoS? We hear 3 main pushbacks from investors: (1) etiology of PSC is still pretty unclear (2) this novel target lacks PoC in pts (3) the dev path in PSC is long/risky without a clear AA oppty right now.
Citizens JMP
$8
Buy
238.98%
Upside
Reiterated
10/15/25
Cantor Fitzgerald
$8
Buy
238.98%
Upside
Reiterated
07/17/25
JonesTrading
$11
Buy
366.10%
Upside
Reiterated
05/17/25
We are at ASGCT this week and caught ProQR's oral session on cholestatic diseases and their two posters on Rett and MASH. Cholestatic Diseases: ProQR presented preclinical data and Ph1 trial design for AX-0810, an RNA editing oligo for cholestatic diseases. Presentation was substantially similar to OTS Meeting, and supports 0810's potential to reduce liver bile accumulation in primary sclerosing cholangitis (PSC). AX-0810 introduces a de novo edit, so Ph1 healthy volunteer data should give us a good picture of in vivo editing capabilities.
Oppenheimer
$15→$9
Buy
281.36%
Upside
Reiterated
05/13/25
Citi
$4
Buy
69.49%
Upside
Upgraded
03/07/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$12
Buy
408.47%
Upside
Reiterated
12/10/25
Positive Outlook for ProQR's AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy RecommendationValuation and Risks. Our price target of $12 is based on a DCF analysis from 2025-2032, with NPV of $12 per share (discounted cash flow analysis using a 20% discount rate and 1% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to our investment thesis and target price include: (1) failure of clinical studies or partnership opportunities; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.
Chardan Capital
$4
Buy
69.49%
Upside
Reiterated
11/06/25
Evercore ISI
$5
Buy
111.86%
Upside
Reiterated
11/04/25
ProQR (PRQR) Receives a Buy from Evercore ISIWe model PSC as a $2B oppty for PRQR (we don’t model BA for now). Candidly, if PRQR has the first truly disease-modifying therapy in PSC, this # should be conservative. But let’s go with it. To reach the current trading price, we find a market-implied 12.5% PoS. After PRQR has their full P1 NTCP HV data in 1H26, we think it’s very reasonable to model a 20% PoS. This would correspond to a $5/sh price – implying 100% upside from now until this PoC data. (25% PoS is also quite defendable, which would correspond to $7/sh) Why not a higher PoS? We hear 3 main pushbacks from investors: (1) etiology of PSC is still pretty unclear (2) this novel target lacks PoC in pts (3) the dev path in PSC is long/risky without a clear AA oppty right now.
Citizens JMP
$8
Buy
238.98%
Upside
Reiterated
10/15/25
Cantor Fitzgerald
$8
Buy
238.98%
Upside
Reiterated
07/17/25
JonesTrading
$11
Buy
366.10%
Upside
Reiterated
05/17/25
We are at ASGCT this week and caught ProQR's oral session on cholestatic diseases and their two posters on Rett and MASH. Cholestatic Diseases: ProQR presented preclinical data and Ph1 trial design for AX-0810, an RNA editing oligo for cholestatic diseases. Presentation was substantially similar to OTS Meeting, and supports 0810's potential to reduce liver bile accumulation in primary sclerosing cholangitis (PSC). AX-0810 introduces a de novo edit, so Ph1 healthy volunteer data should give us a good picture of in vivo editing capabilities.
Oppenheimer
$15→$9
Buy
281.36%
Upside
Reiterated
05/13/25
Citi
$4
Buy
69.49%
Upside
Upgraded
03/07/25
Best Analysts Covering ProQR
1 Month
xxx
Success Rate
7/21 ratings generated profit
Average Return
-9.27%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -9.27% per trade.
3 Months
xxx
Success Rate
10/21 ratings generated profit
Average Return
-3.66%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of -3.66% per trade.
1 Year
Success Rate
13/21 ratings generated profit
Average Return
+9.42%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +9.42% per trade.
2 Years
xxx
Success Rate
12/21 ratings generated profit
Average Return
+1.68%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +1.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PRQR Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
7
5
5
5
6
Buy
0
0
0
0
0
Hold
13
16
12
7
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
21
17
12
9
Each month's total comprises the sum of three months' worth of ratings.
PRQR Financial Forecast
PRQR Stock Forecast FAQ
What is PRQR’s average 12-month price target, according to analysts?
Based on analyst ratings, ProQR’s 12-month average price target is 7.25.
What is PRQR’s upside potential, based on the analysts’ average price target?
ProQR has 207.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRQR a Buy, Sell or Hold?
ProQR has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is ProQR’s price target?
The average price target for ProQR is 7.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $4.00. The average price target represents 207.20% Increase from the current price of $2.36.
The highest analyst price target is $12.00 ,the lowest forecast is $4.00. The average price target represents 207.20% Increase from the current price of $2.36.
What do analysts say about ProQR?
ProQR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of PRQR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.